Safety and Efficacy of Adjunct Therapies in Adults With Type 1diabetes: Multicenter, Registry Study
Status: Recruiting
Location: See all (7) locations...
Study Type: Observational
SUMMARY
This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adults ≥18 years of age
• Clinical diagnosis of T1D
• GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
• Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
• Willing and able to provide informed consent
Locations
United States
California
Hoag Memorial Hospital
RECRUITING
Newport Beach
Georgia
Emory University
RECRUITING
Atlanta
Illinois
Northwestern University
RECRUITING
Chicago
Massachusetts
Harvard Medical School
RECRUITING
Boston
Maine
Maine Health Research Institute
RECRUITING
Portland
Michigan
Henry Ford Hospital
RECRUITING
Detroit
New York
Mount Sinai
RECRUITING
New York
Contact Information
Primary
Kanchan Bhasin, MBBS
kanbhas@iu.edu
(317)-278-2752
Time Frame
Start Date: 2026-03-24
Estimated Completion Date: 2028-04
Participants
Target number of participants: 300
Related Therapeutic Areas
Sponsors
Collaborators: Jaeb Center for Health Research
Leads: Indiana University